Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
2.790
-0.040 (-1.41%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.

The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.

The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Puma Biotechnology, Inc.
Puma Biotechnology logo
Country United States
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 185
CEO Alan Auerbach

Contact Details

Address:
10880 Wilshire Boulevard, Suite 2150
Los Angeles, California 90024
United States
Phone 424 248 6500
Website pumabiotechnology.com

Stock Details

Ticker Symbol PBYI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001401667
CUSIP Number 74587V107
ISIN Number US74587V1070
Employer ID 77-0683487
SIC Code 2834

Key Executives

Name Position
Alan H. Auerbach Founder, Chairman, President, Chief Executive Officer and Secretary
Maximo F. Nougues Chief Financial Officer and Principal Accounting Officer
Douglas Hunt B.Sc., FRAPS Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance and Law Officer
Jeffrey Jerome Ludwig Chief Commercial Officer
Mariann Ohanesian Senior Director of Investor Relations
Dr. Bo H. Chao Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Oct 22, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 16, 2024 8-K Current Report
Aug 27, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 15, 2024 8-K Current Report
Aug 12, 2024 144 Filing
Aug 7, 2024 8-K Current Report
Aug 1, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
Jul 17, 2024 144 Filing
Jul 17, 2024 144 Filing